Daré Bioscience Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Daré Bioscience de 62.5% y 57.7% respectivamente, mientras que el BPA crecerá en un 61% al año.
Información clave
62.5%
Tasa de crecimiento de los beneficios
60.98%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.4% |
| Tasa de crecimiento de los ingresos | 57.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 09 Apr 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 134 | 69 | N/A | N/A | 2 |
| 12/31/2027 | 50 | 9 | N/A | N/A | 2 |
| 12/31/2026 | 0 | -19 | N/A | N/A | 2 |
| 12/31/2025 | 1 | -13 | -10 | -10 | N/A |
| 9/30/2025 | 0 | -17 | -7 | -6 | N/A |
| 6/30/2025 | 0 | -19 | -12 | -12 | N/A |
| 3/31/2025 | 0 | -2 | 6 | 7 | N/A |
| 12/31/2024 | 0 | -4 | 5 | 5 | N/A |
| 9/30/2024 | 2 | -4 | -9 | -8 | N/A |
| 6/30/2024 | 3 | -7 | -11 | -10 | N/A |
| 3/31/2024 | 3 | -29 | -30 | -30 | N/A |
| 12/31/2023 | 3 | -30 | -39 | -39 | N/A |
| 9/30/2023 | 1 | -41 | -37 | -37 | N/A |
| 6/30/2023 | N/A | -40 | -20 | -20 | N/A |
| 3/31/2023 | 10 | -31 | -22 | -22 | N/A |
| 12/31/2022 | 10 | -31 | -18 | -18 | N/A |
| 9/30/2022 | 10 | -25 | -22 | -22 | N/A |
| 6/30/2022 | 10 | -30 | -29 | -29 | N/A |
| 3/31/2022 | N/A | -40 | -33 | -33 | N/A |
| 12/31/2021 | N/A | -39 | -29 | -29 | N/A |
| 9/30/2021 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2021 | N/A | -33 | -35 | -35 | N/A |
| 3/31/2021 | N/A | -30 | -27 | -27 | N/A |
| 12/31/2020 | N/A | -27 | -25 | -25 | N/A |
| 9/30/2020 | N/A | -23 | -20 | -20 | N/A |
| 6/30/2020 | N/A | -19 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -16 | -17 | -17 | N/A |
| 12/31/2019 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2019 | N/A | -14 | N/A | -12 | N/A |
| 6/30/2019 | N/A | -13 | N/A | -12 | N/A |
| 3/31/2019 | N/A | -12 | N/A | -11 | N/A |
| 12/31/2018 | N/A | -17 | N/A | -10 | N/A |
| 9/30/2018 | N/A | -23 | N/A | -9 | N/A |
| 6/30/2018 | N/A | -22 | N/A | -7 | N/A |
| 3/31/2018 | N/A | -19 | N/A | -5 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -3 | N/A |
| 9/30/2017 | N/A | -3 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | 0 | N/A |
| 3/31/2017 | N/A | -1 | N/A | 0 | N/A |
| 12/31/2016 | N/A | -1 | N/A | 0 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que DARE sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que DARE sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que DARE sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (57.7% al año) de DARE crezcan más rápidamente que los del mercado US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (57.7% al año) de DARE crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DARE se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/14 02:19 |
| Precio de las acciones al final del día | 2026/05/14 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Daré Bioscience, Inc. está cubierta por 5 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |